JP7162693B1 - 馬乳酒由来エクソソーム及びその使用 - Google Patents
馬乳酒由来エクソソーム及びその使用 Download PDFInfo
- Publication number
- JP7162693B1 JP7162693B1 JP2021070665A JP2021070665A JP7162693B1 JP 7162693 B1 JP7162693 B1 JP 7162693B1 JP 2021070665 A JP2021070665 A JP 2021070665A JP 2021070665 A JP2021070665 A JP 2021070665A JP 7162693 B1 JP7162693 B1 JP 7162693B1
- Authority
- JP
- Japan
- Prior art keywords
- horse
- exosomes
- composition
- derived
- tarc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 96
- 235000020252 horse milk Nutrition 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 claims abstract description 23
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 8
- 230000001404 mediated effect Effects 0.000 claims abstract description 7
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims abstract 8
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 66
- 241000283073 Equus caballus Species 0.000 abstract description 34
- 239000004310 lactic acid Substances 0.000 abstract description 33
- 235000014655 lactic acid Nutrition 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 abstract description 6
- 235000013336 milk Nutrition 0.000 abstract description 6
- 239000008267 milk Substances 0.000 abstract description 6
- 210000004080 milk Anatomy 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 102000003826 Chemokine CCL17 Human genes 0.000 description 32
- 108010082169 Chemokine CCL17 Proteins 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 8
- 238000005199 ultracentrifugation Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010001742 Allergy to animal Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000044064 human CCL17 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- -1 inhalants Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
馬乳酒に由来するエクソソームは、例えば、以下の工程を経ることにより得ることができる。
(a)原料とする馬乳酒を遠心ないしフィルターろ過の処理に供して夾雑物を除去する
(b)上記工程(a)を経て夾雑物を除去した試料を超遠心の処理に供する
(c)上記工程(b)の処理による沈殿物を回収する
後述する試験例に示されるように、馬乳酒由来エクソソームによれば、炎症反応を惹起した正常ヒト表皮角化細胞が産生するTARCの産生を抑制する作用効果がある。
(a)馬乳酒由来エクソソームを含有する皮膚処置用組成物
(b)馬乳酒由来エクソソームを含有する抗炎症用組成物
(c)馬乳酒由来エクソソームを含有するTARC産生抑制用組成物
(d)馬乳酒由来エクソソームを含有するアトピー性皮膚炎処置用組成物
(e)馬乳酒由来エクソソームを有効成分とするTARC産生抑制剤
(f)馬乳酒由来エクソソームを有効成分とするTARC産生抑制剤を含有する疾患処置用組成物
馬乳酒(原産国:モンゴル国)を準備し、その50mLを低速遠心(2000×g、5分)にかけて細胞破砕物等の夾雑物を除去した。次いで、37℃に保温しつつ500μLの酢酸溶液を加えて転倒混和したのち、遠心機(12,000×g、10分、4℃)にかけて、その上清を新しいチューブに回収した。これを超遠心装置(ベックマン社製、100,000×g、70分、4℃)にかけて、その沈降画分を回収した。沈渣はPBS(-)に分散させ、同様の超遠心を繰り返し、洗浄、夾雑タンパク質を除去した。最終的にこれをPBS(-)に懸濁させて、以下の試験に用いた。
正常ヒト表皮角化細胞(商品名「正常ヒト表皮角化細胞(成人、単一ドナー):Normal Human Epidermal Keratinocytes (NHEK), adult donor, single donor」、PromoCell社製)を、常法に従い、ケラチノサイト専用培地(商品名「角化細胞増殖培地2キット:Keratinocyte Growth Medium 2 Kit」、PromoCell社製)を用いて、5%CO2、37℃下に75cm2の平底プレート培養容器でサブコンフルエントになるまで培養した。継代のため、新たな培養容器に40%コンフルエントの細胞濃度となるよう播種した後、更に、48時間培養後、6-ウエルプレートに80%コンフルエントの細胞濃度で播種した。24時間培養後、IL-10を終濃度10ng/mLとなるように、TNF-αを終濃度10ng/mLとなるように、IFN-γを終濃度10ng/mLとなるように、それぞれを添加し、更に、24時間培養した。そして、その24時間培養後の培養液に、馬乳酒由来エクソソームを終濃度2μg/mL又は10μg/mLとなるように添加した。
Claims (7)
- 馬乳酒由来エクソソームを含有する皮膚処置用組成物。
- 馬乳酒由来エクソソームを含有する抗炎症用組成物。
- 馬乳酒由来エクソソームを含有するTARC産生抑制用組成物。
- 馬乳酒由来エクソソームを含有するアトピー性皮膚炎処置用組成物。
- 馬乳酒由来エクソソームを有効成分とするTARC産生抑制剤。
- 請求項5記載のTARC産生抑制剤を含有する疾患処置用組成物であって、前記疾患がTARC媒介性疾患である、該組成物。
- 請求項5記載のTARC産生抑制剤を含有する疾患処置用組成物であって、前記疾患がアトピー性皮膚炎である、該組成物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021070665A JP7162693B1 (ja) | 2021-04-19 | 2021-04-19 | 馬乳酒由来エクソソーム及びその使用 |
EP22791424.9A EP4302769A1 (en) | 2021-04-19 | 2022-03-16 | Kumis-derived exosome and use thereof |
US18/287,590 US20240207320A1 (en) | 2021-04-19 | 2022-03-16 | Kumis-derived exosome and use thereof |
CN202280029304.3A CN117897164A (zh) | 2021-04-19 | 2022-03-16 | 源自马奶酒的外泌体及其用途 |
PCT/JP2022/011880 WO2022224644A1 (ja) | 2021-04-19 | 2022-03-16 | 馬乳酒由来エクソソーム及びその使用 |
TW111111345A TW202245815A (zh) | 2021-04-19 | 2022-03-25 | 源自馬奶酒之胞外體及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021070665A JP7162693B1 (ja) | 2021-04-19 | 2021-04-19 | 馬乳酒由来エクソソーム及びその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP7162693B1 true JP7162693B1 (ja) | 2022-10-28 |
JP2022168346A JP2022168346A (ja) | 2022-11-08 |
Family
ID=83722825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021070665A Active JP7162693B1 (ja) | 2021-04-19 | 2021-04-19 | 馬乳酒由来エクソソーム及びその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240207320A1 (ja) |
EP (1) | EP4302769A1 (ja) |
JP (1) | JP7162693B1 (ja) |
CN (1) | CN117897164A (ja) |
TW (1) | TW202245815A (ja) |
WO (1) | WO2022224644A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016056119A (ja) | 2014-09-09 | 2016-04-21 | 森永乳業株式会社 | アポトーシス抑制剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3192518T3 (da) | 2014-09-09 | 2021-04-06 | Morinaga Milk Industry Co Ltd | Anti-inflammatorisk middel |
CN113382773A (zh) | 2019-02-01 | 2021-09-10 | 达芬奇环球有限公司 | 控制生物功能的新成分 |
-
2021
- 2021-04-19 JP JP2021070665A patent/JP7162693B1/ja active Active
-
2022
- 2022-03-16 WO PCT/JP2022/011880 patent/WO2022224644A1/ja active Application Filing
- 2022-03-16 US US18/287,590 patent/US20240207320A1/en active Pending
- 2022-03-16 EP EP22791424.9A patent/EP4302769A1/en active Pending
- 2022-03-16 CN CN202280029304.3A patent/CN117897164A/zh active Pending
- 2022-03-25 TW TW111111345A patent/TW202245815A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016056119A (ja) | 2014-09-09 | 2016-04-21 | 森永乳業株式会社 | アポトーシス抑制剤 |
Non-Patent Citations (5)
Title |
---|
Biochim. Open, (2017), 4, p.61-72 |
J. Agric. Food Chem., (2017), 65, [6], p.1220-1228 |
Jpn. J. Lactic Acid Bact., (2011), 22, [3], p.153-161 |
ミルクサイエンス, (2015), 64, [1], p.53-62 |
日本栄養・食糧 学会誌, (2002), 55, [5], p.281-285 |
Also Published As
Publication number | Publication date |
---|---|
US20240207320A1 (en) | 2024-06-27 |
WO2022224644A1 (ja) | 2022-10-27 |
EP4302769A1 (en) | 2024-01-10 |
CN117897164A (zh) | 2024-04-16 |
TW202245815A (zh) | 2022-12-01 |
JP2022168346A (ja) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11612621B2 (en) | Use of composition comprising exosome derived from adipose-derived stem cell as effective ingredient in ameliorating dermatitis | |
EP1895973B1 (en) | Purified extracts of blue-green algae and method of use | |
US11446333B2 (en) | Use of composition comprising stem cell-derived exosome as effective ingredient for suppression or alleviation of pruritus | |
JP2021152041A (ja) | 治療方法 | |
US20210386825A1 (en) | Osteoarthritis Treatment With Chemokine-Loaded Alginate Microparticles | |
KR20190003383A (ko) | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 | |
WO2021147923A1 (zh) | 一种囊泡及其应用 | |
JP2021510300A (ja) | フィーカリバクテリウム・プラウスニッツィイ由来のナノ小胞およびその用途 | |
KR20190096286A (ko) | 락토코커스 속 세균 유래 나노소포 및 이의 용도 | |
JP7478227B2 (ja) | 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法 | |
JP7162693B1 (ja) | 馬乳酒由来エクソソーム及びその使用 | |
Bansal et al. | A Short Study Report on Bone Marrow Aspirate Concentrate Cell Therapy in Ten South Asian Indian Patients with Autism. | |
JP2022516988A (ja) | デイノコッカス属細菌由来ナノ小胞及びその用途 | |
CN111686118B (zh) | 油酰基-L-α-溶血磷脂酸在制备自然流产保胎药物中的应用 | |
WO2024048161A1 (ja) | 抗酸化剤、および線維芽細胞促進剤 | |
JP7054956B2 (ja) | リゾビウム属細菌由来のナノ小胞およびその用途 | |
JP2022517962A (ja) | ロドコッカス属細菌由来ナノ小胞およびその用途 | |
CN116440166A (zh) | 一种用于抗衰焕活或愈伤的生物制品及其制备方法和应用 | |
JP2023521545A (ja) | 修飾マクロファージ、組成物およびその使用 | |
TW202332764A (zh) | 用於生產外泌體的方法及其所製得的外泌體暨其應用 | |
TW201912853A (zh) | 篩選抑制發炎反應及血管保護活性物質之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220726 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220927 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221018 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7162693 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |